ArticleJOR spine2026
Lost in Translation: Why Biologic Therapies for Intervertebral Disc Degeneration and Low Back Pain Have Not Reached the Clinic (Yet): Bridging Biology, Pain Phenotyping, and Trial Design.
Article in JOR spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From preclinical promise to clinical translation in intervertebral disc degeneration (IDD). Robust preclinical evidence supports a range of biologic therapies, with consistent improvements in imaging, extracellular matrix composition, inflammation, and behavior. However, a substantial translational gap persists, driven by key challenges including the discordance between IDD and pain, patient heterogeneity, inadequate phenotyping, placebo effects, limitations of preclinical models, hostile disc microenvironment, and practical/clinical trial barriers. A precision medicine framework is crucial to overcome these limitations, based on improved patient stratification, definition of molecular and clinical endotypes linked to targeted therapies, integration of advanced biomarkers, development of more sensitive outcome measures, and optimization of clinical trial design, ultimately aiming to enable successful clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.